EGFR and lung carcinoma: We next analyzed the public scRNA-seq data of consecutive biopsies at the treatment naïve (TN), residual disease (RD) and progressive disease (PD) stage from an EGFR-mutant lung cancer patient with squamous transition along with TKI therapy failure (Fig. S4F and G) [31].